These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29880583)

  • 1. A Secondary Mutation in
    Wang J; Yao Z; Jonsson P; Allen AN; Qin ACR; Uddin S; Dunkel IJ; Petriccione M; Manova K; Haque S; Rosenblum MK; Pisapia DJ; Rosen N; Taylor BS; Pratilas CA
    Cancer Discov; 2018 Sep; 8(9):1130-1141. PubMed ID: 29880583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Dabrafenib for three children with brainstem BRAF
    Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
    J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
    Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
    Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
    J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent ganglioglioma in adults treated with BRAF inhibitors.
    Chamberlain MC
    CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib therapy for advanced melanoma.
    Trinh VA; Davis JE; Anderson JE; Kim KB
    Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
    Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA
    PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
    Falchook GS; Trent JC; Heinrich MC; Beadling C; Patterson J; Bastida CC; Blackman SC; Kurzrock R
    Oncotarget; 2013 Feb; 4(2):310-5. PubMed ID: 23470635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in
    Hazar-Rethinam M; Kleyman M; Han GC; Liu D; Ahronian LG; Shahzade HA; Chen L; Parikh AR; Allen JN; Clark JW; Kwak EL; Faris JE; Murphy JE; Hong TS; Van Seventer EE; Nadres B; Hong CB; Gurski JM; Jessop NA; Dias-Santagata D; Iafrate AJ; Van Allen EM; Corcoran RB
    Cancer Discov; 2018 Apr; 8(4):417-427. PubMed ID: 29431697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
    Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.